Catalyst Pharmaceuticals Inc

CPRX has entered a Stage 3 distribution phase, failing to clear early‐May highs and triggering an active Bullish Exhaustion pattern. Short‐term EMAs have flattened and price is extended above the 9/20/50 EMA zone, increasing pullback risk. Medium‐term bias is bearish under distribution, so execution now on a rejection or rollover near the prior highs and EMAs is recommended to participate in further distribution.

• ↑2025 revenue up 19.8% YoY to $589M, exceeding guidance.
• ↑Ferdaps net revenue reached $358.4M (+17%) with ~85% patient retention.
• ↓FICOMPA revenue forecast drops to $40–45M after patent expiry.